Drug profile · INN
telaprevir
INCIVO
telaprevir (INCIVO) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — telaprevir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 2
- Programs
- 12
- Data quality
- 0.89
Quick answer
telaprevir (INCIVO) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Primary target: Hepatitis C virus serine protease, NS3/NS4A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is telaprevir?
telaprevir (INCIVO) is a hepatitis c virus serine protease, ns3/ns4a inhibitor. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for telaprevir?
INCIVO is a marketed brand name for telaprevir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of telaprevir?
telaprevir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.